Introduction to sotorasiib targeted drug

Sotorasib is an oral targeted drug that specifically targets the KRAS G12C gene mutation. KRASGene mutations are common in a variety of cancers, especially in non-small cell lung cancer (NSCLC), KRAS G12C mutations account for about 13% of NSCLC mutations. Since KRAS mutations have long been considered a difficult “undruggable” target, the emergence of sotorasib marks a major breakthrough in cancer treatment. It was approved by the FDA in 2021 for the treatment of patients with KRAS G12C mutated advanced NSCLC who have failed at least one systemic therapy.

Sotorasiib inhibits the proliferation and spread of cancer cells by irreversibly binding KRAS G12C mutant protein and blocking its signaling pathway. The mechanism of action of sotoracib is different from other targeted drugs. It specifically acts on the mutation site on the KRAS protein and is highly targeted. Therefore, it has a significant effect in patients with KRAS G12C mutation-positive patients. Clinical studies have shown that sotoraxib has a high effective rate and disease control rate, can significantly delay the progression of the disease, and shows good tolerability in some patients.

However, sotorasiib also has some common side effects, including diarrhea, fatigue, nausea, elevated transaminases, etc. During use, patients need to regularly monitor liver function to avoid potential liver toxicity. In addition, the efficacy of sotoraxib may decrease due to drug resistance after long-term treatment, so studies in combination with other targeted drugs or immunotherapy are also being explored to deal with the problem of drug resistance.

Currently, sotoracib is not available in China, but patients can purchase it overseas. With the accumulation of more clinical data, sotoraxib is expected to further expand its indications and benefit more cancer patients.